Approximately one third of patients with symptomatic indolent lymphoma (30% with FL, 23% without FL) did not need new therapy in the long term after first-line rituximab without chemotherapy. In the entire cohort, 10-year survival was excellent with no major safety issues, which suggests that chemotherapy can be delayed safely in the majority of patients.
Purpose
For indolent lymphoma, the optimal timing, sequence, and choice of therapeutic regimens remain a matter of debate. In two Nordic Lymphoma Group randomized trials, symptomatic or clearly progressing patients were treated first line with a rituximab-containing regimen without chemotherapy. The purpose of this study was to assess long-term survival, risk of transformation, and need of new therapies.
Methods
Data were collected at cross-sectional follow-up for 321 patients with indolent lymphoma (84% with follicular lymphomas [FL] ) included in one of two Nordic Lymphoma Group trials (accrual 1998 to 1999 and 2002 to 2008) . All patients received first-line therapy with one or two cycles of four weekly infusions of rituximab 375 mg/m 2 , and 148 were randomly allocated to the addition of interferon alfa-2a. Follow-up data were retrieved from initial trial databases and medical records on repeated clinical evaluations.
Results
At the end of follow-up, 73% of patients were alive, with a median follow-up after random assignment of 10.6 years. Among all, 36% (38% with FL) had never needed chemotherapy. For patients with FL who required new therapy within 24 months because of early disease progression, the 10-year survival rate was 59% versus 81% for those with longer remission. Interferon was not shown to improve long-term outcome. Transformation was diagnosed in 20% of all patients (2.4% per person-year) and in 18% with FL. An additional malignancy was found in 12%.
INTRODUCTION
Indolent lymphoma is a term used to describe a group of B-cell lymphomas characterized by a slow development. Therapeutic options are abundant and initial responses usually good, but most patients experience several relapses. Generalized disease is considered incurable. 1, 2 The prognosis for patients with CD20 + lymphomas significantly improved with the introduction of the antibody rituximab. For patients with follicular lymphoma (FL) in general, the median survival from diagnosis now reaches approximately 20 years. 2 In a large randomized trial by Ardeshna et al, 3 patients with advancedstage asymptomatic disease had a prolonged progression-free survival with rituximab compared with watchful waiting but no survival benefit. In view of the lacking evidence that early therapy will prolong life, watch and wait is still a valid strategy.
Symptomatic patients and those with high tumor burden are treated mostly with rituximab in combination with chemotherapy. However, the optimal timing, sequence, and choice of regimens remain a matter of debate. 4, 5 The Nordic Lymphoma Group (NLG) performed two randomized clinical trials (M39035 accrual 1998 to 1999 and ML16865 accrual 2002 to 2008) that omitted chemotherapy upfront. The aims were to maintain survival while reducing both short-and long-term adverse effects, such as cardiotoxicity and second primary cancer. 6, 7 In total, 439 patients with indolent B-cell lymphoma with generalized symptomatic disease in need of therapy were randomly assigned to rituximab monotherapy or rituximab combined with interferon alfa-2a (IFNa-2a). The rationale for the addition of IFN was to sensitize B cells by increasing their CD20 expression and to potentiate antibodydependent cellular cytotoxicity by stimulation of T and natural killer cells. [8] [9] [10] [11] In both trials, initial end point analyses favored combination therapy, but benefits did not last. Survival later was perceived to be good enough to enable the current long-term follow-up to assess time to new therapy, transformation, late toxicity, and overall survival (OS). This is of interest because late effects of mere biologic therapy given first line are not well studied. Concerns have been raised about the risk of undertreatment with a higher incidence of transformation and premature death. [12] [13] [14] [15] [16] [17] Because relapse in patients with FL within 24 months after first-line immunochemotherapy (early progression of disease [POD]) was shown to be predictive of a very short OS, 18 we aimed to investigate whether this was also the case after rituximab treatment.
METHODS
Details on the study method are provided in the Data Supplement.
Study Population
The original study population comprised 439 patients randomly assigned to either of two trials: M39035 (n = 126) and ML16865 (n = 313). Eligible for this follow-up were previously untreated patients with FL, marginal zone lymphoma, small lymphocytic lymphoma, and indolent lymphoma not otherwise specified. Patients not fulfilling the diagnostic criteria for indolent lymphoma at biopsy review (n = 12) were excluded. To focus on nodal disease, we also excluded Waldenström macroglobulinemia (n = 10; Fig 1) .
All alive patients were asked for informed consent, including permission for extensive medical file review. Among the 321 patients finally included, 20 were lost to long-term follow-up and excluded from the assessment of infectious complications, transformation, and other cancers. The study was conducted according to the principles of the Declaration of Helsinki and approved by the regional ethical committees in each country (Denmark, Norway, and Sweden).
Data Collection
A case report form for the collection of clinical follow-up data was created and distributed to participating centers. Variables assessed were Medical records not found (n = 9) post-trial therapies with types and dates of initiation, transformation to high-grade disease, episodes of infection, immunoglobulin substitution, late-onset neutropenia (LON), and occurrence of second primary malignancies. Dates of last follow-up or dates and causes of death were noted for live and deceased patients, respectively.
Design of the Original Randomized Trials
The M39035 and ML16865 trials were similar in design. 6, 7 All patients as well as those previously handled with watchful waiting had to be in need of therapy as a result of symptomatic/progressive lymphadenopathy, splenomegaly, cytopenias, and/or B symptoms (Data Supplement). Inclusion criteria were symptomatic, advanced, indolent CD20 + lymphoma; a performance status of 0 to 2; and adequate organ function. Patients with bulky disease were included if there was no threat to organ function.
Therapy consisted of four weekly doses of rituximab (375 mg/m 2 ), and in the case of random assignment to IFN, IFN-a2a and 3 million International Units/d subcutaneously was given on week 1 followed by 4.5 million International Units/d subcutaneously given on weeks 2 to 5 (Data Supplement). Total treatment duration for two cycles, each containing four rituximab doses, was a maximum of 6 months. Response evaluation was made at week 10 after the first cycle, and rituximab-refractory patients (stable or progressive disease) were not eligible for the second cycle. In the first trial, patients who attained complete response already after the first cycle were assigned no additional treatment.
Statistical Considerations
The main end point of OS was estimated from the date of random assignment in the original trials to death or end of follow-up using the Kaplan-Meier method. Comparison of patients who received rituximab only with those who also received IFN was made on an intention-to-treat basis using the log-rank test. All outcomes were investigated separately for patients with FL.
Secondary end points were calculated from the date of random assignment and included time to treatment failure, defined as time to either initiation of any new therapy because of relapse, intolerance, or death as a result of any cause; time to new antilymphoma therapy (TTNT); TTNT restricted to chemotherapy-containing regimens, time to transformation; and lymphoma-specific survival (LSS). Definitions of each secondary end point are provided in the Data Supplement.
We defined time to progression as identical to the more robust TTNT. Survival on the basis of POD status at 24 months was compared between two groups of patients: those with early POD, defined as having progressed # 2 years from randomization, and a reference group without early POD. For patients with early POD, survival was calculated from the date of the first new therapy. For those with longer remission (. 2 years), time 0 was set to the date of random assignment plus 2 years, as in the LymphoCare Study. 18 Patients with early POD lost to follow-up at their date of first post-trial treatment (n = 5) and those without early POD who died within 2 years (n = 9) were excluded from the analyses.
Univariable and multivariable Cox proportional hazards regression models were applied for comparison of outcome by patient subcategories.
The proportional hazards assumption was tested with Schoenfeld residuals with no violations. Incidences of second primary malignancies and infectious complications were compared with x 2 tests. The significance level was set to .05, and all tests were two-sided. STATA 13.1 software (Stata-Corp, College Station, TX) was used for statistical analyses.
RESULTS
Details on results are provided in the Data Supplement. The characteristics of the 321 patients at original trial inclusion, at 35 centers, are listed in Table 1 . The majority (88%) had Ann Arbor stage III to IV cancer. In the FL subgroup, 41% had a poor-risk Follicular Lymphoma International Prognostic Index (FLIPI) 19 score of 3 to 5. Median follow-up overall was 9.8 years (range, 0.1 to 18.8 years) from random assignment.
Outcome Measures
All diagnoses. At end of follow-up, 234 patients (73%) were alive (median, 10.6 years; range, 0.1 to 18.8 years; Fig 2; Table 2 ). The OS rate at 10 and 15 years after random assignment was 75% and 66%, respectively, and the corresponding LSS rates were 81% jco.org and 77%. When calculated since diagnosis, 10-and 15-year OS rates were 78% and 66%, respectively, and the LSS rates were 84% and 77%. For patients who responded to the first cycle (n = 256), 10-and 15-year OS rates were 79% and 68%, respectively, and the LSS rates were 85% and 81%. For patients who did not respond to the first cycle (n = 65), 10-and 15-year OS rates were 58% and 54%, respectively. The adjusted hazard ratio (HR) of death between responders and nonresponders was 0.6 (95% CI, 0.34 to 0.94; P = .03). OS was slightly better for women than for men, but the difference was not significant (Data Supplement).
In total, 117 patients (36%) never required chemotherapy during follow-up (Data Supplement), but of them, 24 were retreated with antibodies and/or radiation. Among patients without a need for new therapy (n = 93) nine died as a result of lymphoma-unrelated causes. For the 237 patients (74%) who fulfilled the criteria of treatment failure, median time to treatment failure was 1.5 years (range, 0.1 to 16.0 years; Data Supplement). Patients with early POD (Data Supplement) had a 10-and 15-year OS rate of 62% and 53%, respectively. For the reference group, the corresponding OS rates were 89% and 78%, with an adjusted HR of 0.3 (95% CI, 0.18 to 0.48; P , .001).
Transformation to aggressive lymphoma occurred in 63 patients; for 26 patients, it was the first chemotherapy-requiring event. In total, 47 patients (75%) had biopsy-proven disease, whereas the remaining had confirmation by cytology or met clinical criteria strongly suggestive of aggressive disease. 20 The overall transformation rate was 2.4% per person-year. At 10 and 15 years after random assignment, the cumulative risk of transformation was 20% and 24% (Fig 3) . In the cohort of all transformed lymphomas, median time to transformation was 4.2 years (Data Supplement). The non-FL subgroup had a slightly higher risk of transformation than the FL group when adjusted for sex and variables included in the FLIPI score (HR, 1.9; 95% CI, 0.99 to 3.65; P = .05). Analysis Time (years) TTF (proportion) With a median follow-up time after transformation of 2.9 years (range, 0.01 to 16.7 years), the 5-year survival rate for all patients with transformed disease was 47%; for those treated with high-dose chemotherapy with stem-cell support (n = 15), the rate was 52%. When transformation was the first post-trial event, median survival for patients in the single rituximab arm (n = 14) was 4.1 years, and when occurring after chemotherapy (n = 21), median survival was 3.4 years. In the rituximab plus IFN arm, the survival difference was greater, where the median was not reached for first-event transformers (n = 16) versus 0.5 years for the others (n = 12).
FL subgroup. With a median follow-up of 10.6 years, 197 patients with FL (73%) were alive ( Fig 2C; Table 2 ). The OS rate at 10 and 15 years after random assignment was 75% and 65%, respectively, and the corresponding LSS rates were 82% and 77%. When calculated since diagnosis, the 10-and 15-year OS rates were 78% and 65%, respectively, and the LSS rates were 85% and 77%. The majority of patients (n = 219) responded to the first trial cycle, obtaining a 10-and 15-year OS rate of 80% and 68%, respectively. Nonresponding patients (n = 50) had an OS rate of 56% at 10 years and 51% at 15 years, with an HR for responders versus nonresponders of 0.5 (95% CI, 0.29 to 0.88; P = .02). Anemia at trial inclusion was less common in the FL subgroup than in the non-FL subgroup, whereas the number of nodal stations involved jco.org was higher (Data Supplement). A high FLIPI score was significantly associated with inferior OS and TTNT (Data Supplement).
In total, 103 patients (38%) never required chemotherapy during follow-up (Data Supplement), but 22 of them received antibodies and/or radiation. Among those who were not retreated, eight died. Patients with FL with early POD (Data Supplement) had 10-and 15-year OS rates of 59% and 48%, respectively, compared with 91% and 80% for the reference group (adjusted HR for death, 0.2; 95% CI, 0.14 to 0.40; P , .001; Fig 4) .
Transformation was diagnosed in 49 patients and confirmed by biopsy in 38. The overall transformation rate was 2.1% per person-year. With a median follow-up time after transformation of 2.2 years (range, 0.01 to 16.7 years), the 5-and 10-year survival rates were 41%.
Second Primary Malignancy
Among the 204 patients with indolent lymphoma who received chemotherapy after the initial protocol treatment, 25 (12%) were reported to have at least one second primary malignancy compared with 12 (10%) among the 117 still free of chemotherapy (P = .74). Six patients developed acute myelomonocytic leukemia/ myelodysplastic syndrome and had received chemotherapy before diagnosis.
Infections and Immunodeficiency
Data on infectious episodes were available for 301 patients ( Table 3 ). In the subgroup with no post-trial therapy (n = 81), two cases of herpes simplex/zoster, one of Pneumocystis jirovecii pneumonia, three of bacterial pneumonia, and two of sepsis were reported. One intracranial abscess and one necrotizing fasciitis were found in patients who had received only radiotherapy after trial rituximab plus IFN. Those who received chemotherapy experienced more episodes of bacterial pneumonia, sepsis, or herpes simplex/zoster and were more often in need of immunoglobulin substitution. Long-term infectious complications among patients who received trial combination therapy were not significantly different from those in the single rituximab arm. With the exception of Pneumocystis jirovecii pneumonia, the listed diagnoses seemed more rare in patients with FL than in patients with other entities, but significance was seen only for herpes simplex/zoster (P = .01). LON was reported in six patients, at least one of whom was still chemotherapy free.
DISCUSSION
The introduction of rituximab in the late 1990s represented the start of a new era. In the current study of first-line rituximab Overall survival (OS) in the follicular lymphoma subgroup by risk group according to time to progression of disease (POD) and initiation of new therapy. Early POD is defined as POD no later than 24 months after random assignment; survival is illustrated since the time of new therapy. For patients without early POD (the reference group) time 0 is set to 24 months after random assignment. Patients with early POD lost to follow-up at first post-trial treatment and those without early POD decease within 2 years are excluded here. Log-rank P , .01. NOTE. Listed are patients who were reported to have been diagnosed with one or more episodes of infectious disease or signs of immunosuppression after end of original trial therapy. Long-term follow-up data missing for 20 patients reduced the counts of all patients and of subgroups by indolent lymphoma subtype (FL or other) and by given therapy. Abbreviations: FL, follicular lymphoma; IFN-a-2a, interferon alfa-2a. *Major is defined as likely to require hospital admission or often relapsing infection. without chemotherapy, three quarters of patients with indolent lymphoma were alive at follow-up (median follow-up after random assignment in NLG trials M39035 and ML16865, 10.6 years). This OS is at least as good as that observed in modern immunochemotherapy trials, such as the recently reported longterm results of the Primary Rituximab and Maintenance trial and others, 21-26 four of which 22,23,25,26 had a shorter follow-up. In fact, two of the trials 21,24 included patients with fewer symptoms, lower tumor burden, and an intermediate rather than a high FLIPI score. Moreover, the duration of therapy was longer and toxicity seemingly higher than in our nonchemotherapy trials.
As OS in patients with lymphoma improves, the burden of late adverse effects becomes a greater concern. In other rituximab trials, most of them including chemotherapy, complications have been reported, including heart failure; LON; intestinal perforation; interstitial pneumonitis; reactivation of viral infections (eg, herpes, hepatitis), and the uncommon, but severe progressive multifocal leukoencephalopathy. [27] [28] [29] Several studies also have suggested an increased overall risk of a second primary cancer after lymphoma therapy, [12] [13] [14] [15] [16] 30 but whether this is due to treatment (chemotherapy, immunosuppression) or inherent to the patient group with shared genetic and/or environmental etiology is unclear. A meta-analysis by Fleury et al 17 showed no such increased risk from rituximab alone after a median follow-up of 6 years. Because many patients in the current study received additional lines of therapy, the role of rituximab plus IFN alone versus immunochemotherapy is difficult to evaluate, but the first-line chemotherapy-free approach might be associated with a reduced risk of LON and second primary malignancies. Again, the question may be whether any reduction is to be explained by a less toxic treatment or immunodeficiency related to a primarily moreaggressive disease that does not respond to rituximab plus IFN and, therefore, requires chemotherapy or both. Few studies have reported on follow-up . 10 years; thus, comparisons of secondary outcomes remain hypothetical.
The population-based registration system with civic numbers unique for each individual and national disease-specific registries used in the Nordic countries facilitate follow-up. Nevertheless, a limitation of this study is the mainly retrospective design. A few patients with no relapse after trial had been dismissed from the clinics, thereby limiting follow-up time with respect to some clinical data. Furthermore, medical files from other hospitals/ departments were not always available; infectious episodes and the need for immunoglobulin substitution are most likely underreported.
Histologic transformation to aggressive lymphoma is reported to occur in 10% to 30% of patients with FL over time and is known to confer a poor prognosis. 31 Lacking a biopsy providing clear histological evidence, there is no consensus definition of transformed FL. The varying incidences reported partially are due to different definitions and diagnostic procedures as well as to the inherent variability among populations, treatment, and follow-up time. Death as a result of other causes constitutes a competing risk that needs to be taken into account. The 10-year cumulative incidence rate of transformation of 20% (2.1% to 2.4% per person-year) observed in the current study is broadly similar to what has been described previously for FL. 23, 30, [32] [33] [34] [35] [36] Of note, our data suggest a relatively constant transformation rate over time, with no plateau within 15 years since initial lymphoma diagnosis.
FL grade 3 traditionally has been considered more aggressive with an increased risk of transformation. 37 In the current cohort with biologic therapy, the survival of patients with FL grade 1 was inferior to that of higher grades, which is in line with some previous reports 38- 40 but not all, 41 and transformation was not more common in grade 3a. Management strategies, including watchful waiting, genotoxic chemotherapy, and rituximab maintenance, may influence not only the risk but also the outcome of transformation. 3, [31] [32] [33] [34] The current results are in line with recent data, suggesting that the risk of transformation in the immunotherapy era has been reduced from a 5-year cumulative incidence rate of approximately 20% to 13% in our cohort, and survival after such an event has improved from a median of 0.6 to 2.7 years 20, 30, 32 to the 4.2 years overall that we found.
Because the term time to progression depends on assessment frequency and quality, we found TTNT to be preferable for comparative analyses because a specific time point was always captured. Compared with the LymphoCare Study, 18 the OS for our patients with therapy-requiring progress within 24 months after first-line treatment was better. Because we estimated time to progression since randomization and not since diagnosis, results are affected by the common wait-and-watch period. More importantly, early relapse or progression after immunochemotherapy arguably is likely to reflect disease aggressiveness, but after initial biologic therapy, second-line chemotherapy may well be effective. This hypothesis is supported by the findings of Maurer et al, 42 who assessed OS in patients with FL according to their event-free survival status at 12 and 24 months. Among patient groups managed with observation, rituximab monotherapy, or immunochemotherapy, early events have been associated with poor outcome, particularly for the latter.
For advanced-stage indolent lymphomas, immunomodulators such as lenalidomide; new antibodies against CD20 and other surface antigens; chimeric antigen receptor T cells; and inhibitors of Bcl-2, phosphatidylinositol 3-kinase, Bruton tyrosine kinase, and checkpoints (some in combination) may prove to be of high potency. [43] [44] [45] The effect of combining agents is reflected in the current study by the relatively large number of patients treated with rituximab plus IFN among the 117 still without need of chemotherapy (Data Supplement). Overtreatment also is a risk with rituximab maintenance, as argued by Friedberg 46 and others in reference to the Rituximab Extended Schedule or Retreatment trial that compared maintenance with retreatment in low-tumor-burden disease. 47, 48 In conclusion, our data indicate that a chemotherapy-free initial approach in patients with indolent lymphoma is associated with an OS comparable with that found in other studies of first-line immunochemotherapy. Adverse effects are few for both the short and the long term. By acknowledging that the chemotherapy-free approach is still a matter of debate, 49-52 the current study shows that a substantial proportion of patients do not need chemotherapy, even after a long followup time. 
